Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the ...

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ...